ライフサイエンスコーパス: sarcoidosis

1 -> uncomplicated sarcoidosis --> complicated sarcoidosis).

2 and nervous system involvement (complicated sarcoidosis).

3 nt ACE levels in 148 patients diagnosed with sarcoidosis.

4 monocyte and macrophage hyper-activation in sarcoidosis.

5 vement occurs in perhaps 5% of patients with sarcoidosis.

6 ted in the peripheral blood of patients with sarcoidosis.

7 MC gene expression is useful in diagnosis of sarcoidosis.

8 ower in the lacrimal gland for patients with sarcoidosis.

9 obtained from 12 historical individuals with sarcoidosis.

10 he orbital adipose tissue from patients with sarcoidosis.

11 atous disease with clinical implications for sarcoidosis.

12 vide diagnostic information in patients with sarcoidosis.

13 signaling pathway in the genetic etiology of sarcoidosis.

14 ermatologists and nondermatologists treating sarcoidosis.

15 s and in peripheral blood from patients with sarcoidosis.

16 or VT ablation, 21 patients (5%) had cardiac sarcoidosis.

17 r level of IgG reactivities in patients with sarcoidosis.

18 ds are the standard first-line treatment for sarcoidosis.

19 ual tests correctly identified patients with sarcoidosis.

20 athy, suggesting frequently the diagnosis of sarcoidosis.

21 butor to spontaneous resolution of pulmonary sarcoidosis.

22 gical index (CPI) in patients with pulmonary sarcoidosis.

23 verting enzyme (SACE) measurement to exclude sarcoidosis.

24 for evaluation of known or suspected cardiac sarcoidosis.

25 agnostic modalities and treatment of cardiac sarcoidosis.

26 ystem for determining prognosis in pulmonary sarcoidosis.

27 entral nervous system (CNS) complications of sarcoidosis.

28 anulomas is recommended for the diagnosis of sarcoidosis.

29 ymphadenopathy in Hodgkin's lymphoma than in sarcoidosis.

30 ulomas in patients with a final diagnosis of sarcoidosis.

31 surement is widely used for the diagnosis of sarcoidosis.

32 y surface area and had evidence of pulmonary sarcoidosis.

33 effect of different treatments on cutaneous sarcoidosis.

34 verity among patients with chronic cutaneous sarcoidosis.

35 rdial inflammation in patients with systemic sarcoidosis.

36 that accurately predict Behcet's disease and sarcoidosis.

37 f bronchoalveolar lavage in the diagnosis of sarcoidosis.

38 on B-cell ablative therapy in patients with sarcoidosis.

39 ocal inflammatory processes in patients with sarcoidosis.

40 e activity in inflammatory disorders such as sarcoidosis.

41 iseases such as leukemia, kidney disease and sarcoidosis.

42 ardial involvement in patients with systemic sarcoidosis.

43 ts are effective but suspensive in cutaneous sarcoidosis.

44 d patients with uncomplicated or complicated sarcoidosis.

45 iabetes mellitus, syphilis, tuberculosis and sarcoidosis.

46 for patients with known or suspected cardiac sarcoidosis.

47 outcome of CA of VT in patients with cardiac sarcoidosis.

48 ferred to MRI for known or suspected cardiac sarcoidosis.

49 eceptors on blood monocytes in patients with sarcoidosis.

50 ated sarcoidosis, and finally to complicated sarcoidosis.

51 cells are a prominent source of IFN-gamma in sarcoidosis.

52 ed as a useful tool for diagnosis of cardiac sarcoidosis.

53 thways may prove to be a novel treatment for sarcoidosis.

54 nd in lung lavage, invoking Th17 immunity in sarcoidosis.

55 of patients with known or suspected cardiac sarcoidosis.

56 that is associated with a good prognosis in sarcoidosis.

57 rohn's disease, Wegener's granulomatosis, or sarcoidosis.

58 rchitecture or its broader phenotype, non-LS sarcoidosis.

59 sy-proven extracardiac diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile

60 iagnosis was made in 36.1% of patients, with sarcoidosis (22.6%) and multiple sclerosis (4.6%) the mo

61 Of 15 130 subjects with sarcoidosis, 3364 (22.2%) were evaluated in an eye clini

62 rticipants included 12 patients with orbital sarcoidosis (7 in adipose tissue; 5 affecting the lacrim

63 se, 12 were consistent with the diagnosis of sarcoidosis, 9 were typical for (prior) tuberculosis, an

64 al study evaluating the use of the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) a

65 tivity and Morphology Instrument (CSAMI) and Sarcoidosis Activity and Severity Index (SASI) to assess

66 uncomplicated sarcoidosis), however, 20% of sarcoidosis-affected individuals experience progressive

67 ystem disorder of unknown cause, and cardiac sarcoidosis affects at least 25% of patients and account

68 kinase responsible for activation of p38 in sarcoidosis alveolar macrophages (AMs) and PBMCs.

69 re reliable and valid in assessing cutaneous sarcoidosis among our diverse group of specialists.

70 tified that sustained p38 phosphorylation in sarcoidosis AMs and PBMCs is associated with active MAPK

71 Additionally, we found that sarcoidosis AMs exhibit a higher expression of IRAK1, IR

72 Surprisingly, ex vivo treatment of sarcoidosis AMs or PBMCs with IRAK1/4 inhibitor led to a

73 n spiral CT was reviewed in 39 patients with sarcoidosis and 37 patients with Hodgkin's lymphoma usin

74 70) was genotyped in 41 subjects with ocular sarcoidosis and 393 control subjects.

75 ation of BALF exosomes from 15 patients with sarcoidosis and 5 healthy control subjects and verified

76 o >100 cells per microliter in patients with sarcoidosis and a fivefold depletion of the slan-positiv

77 granulomatous inflammation characteristic of sarcoidosis and by an increased appreciation of how sarc

78 Although sarcoidosis and celiac disease are both chronic immunolo

79 Associations of sarcoidosis and celiac disease are rare but do occur.

80 veolar lavage-derived cells of subjects with sarcoidosis and control subjects, as well as the effects

81 e (BAL) and serum samples from patients with sarcoidosis and healthy and diseased control subjects to

82 differentially expressed (DE) genes between sarcoidosis and healthy control monocytes.

83 Gene expression profiles of sarcoidosis and healthy control peripheral blood mononuc

84 y for the purpose of differentiation between sarcoidosis and Hodgkin's lymphoma.

85 including inflammatory bowel disease (IBD), sarcoidosis and inflammatory arthritis, making pharmacol

86 Fifty-one patients with cardiac sarcoidosis and left ventricular ejection fraction >35%

87 brillation or death in patients with cardiac sarcoidosis and left ventricular ejection fraction >35%.

88 ical criteria, the presence of extra-cardiac sarcoidosis and LVEF.

89 alid outcome instrument to measure cutaneous sarcoidosis and may capture a wide range of body surface

90 erize the antibody repertoire in relation to sarcoidosis and potentially related autoantigens.

91 k of adverse events in patients with cardiac sarcoidosis and preserved ejection fraction in the absen

92 etic resonance in patients with extracardiac sarcoidosis and preserved left ventricular ejection frac

93 ch to the management of pulmonary disease in sarcoidosis and provide details about how and when to us

94 genesis of psoriasis, and the coexistence of sarcoidosis and psoriasis is mechanistically plausible b

95 We report a case series of 7 patients with sarcoidosis and psoriasis vulgaris.

96 We report a case series of concomitant sarcoidosis and psoriasis, suggesting that common pathog

97 Included patients had histologically proven sarcoidosis and received anti-TNF between January 2004 a

98 Of the 46 patients with sarcoidosis and skin involvement who were treated with a

99 rditis, eosinophilic myocarditis, or cardiac sarcoidosis and those <15 years of age were excluded fro

100 avage fluid (BALF) exosomes in patients with sarcoidosis and to find candidates for disease biomarker

101 pathogenesis of pulmonary diseases including sarcoidosis and tuberculosis are needed to develop new t

102 ranscriptional signature was present in both sarcoidosis and tuberculosis, with a higher abundance an

103 Patients with cardiac sarcoidosis and VT exhibit ventricular substrate charact

104 In patients with cardiac sarcoidosis and VT, CA is effective in achieving long-te

105 Three of these patients also had cutaneous sarcoidosis, and 1 of these patients had evidence of bot

106 ogically confirmed IgG4-RD, 11 patients with sarcoidosis, and 30 healthy subjects were included for 1

107 recognition of cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis and imaging tec

108 are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.

109 dnexal tissue, such as lymphoma, hemangioma, sarcoidosis, and dermoid cyst.

110 erved from healthy control, to uncomplicated sarcoidosis, and finally to complicated sarcoidosis.

111 2 treatment-related events (cardiac failure, sarcoidosis, and foot fracture, all in bevacizumab-treat

112 nulomatous diseases, such as tuberculosis or sarcoidosis, and is decisive for disease pathogenesis.

113 toimmune diseases (e.g., multiple sclerosis, sarcoidosis, and juvenile rheumatoid arthritis).

114 ding idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pul

115 -0.90]) and the Skin Stigma raw score of the Sarcoidosis Assessment Tool (Pearson product moment corr

116 The Sarcoidosis Assessment Tool (SAT), a sarcoidosis-specifi

117 t these T cells are recognizing the putative sarcoidosis-associated Ag(s) in the context of DR3.

118 hy and diseased control subjects to discover sarcoidosis-associated autoantigens.

119 Four proteins are here proposed as sarcoidosis-associated autoimmune targets and of interes

120 New and improved diagnostic tests for sarcoidosis-associated uveitis are needed because the cu

121 Although patients with sarcoidosis-associated uveitis had the highest mean (SD)

122 ensitivity of the bronchoalveolar lavage for sarcoidosis based on CD4/CD8 ratio was 54% (95% CI, 46%-

123 ge, 55+/-10 years) with diagnosis of cardiac sarcoidosis based on Heart Rhythm Society criteria and V

124 cular manifestations of Behcet's disease and sarcoidosis) based on multicolor flow cytometry.

125 and provide suggestions for highly warranted sarcoidosis biomarkers.

126 These data suggest that in sarcoidosis, both pathways, namely IRAK and Rip2, are de

127 ns, spontaneous release of IL-2 was noted in sarcoidosis bronchoalveolar lavage CD4(+) T cells.

128 sy may be increased, especially in suspected sarcoidosis, by the use of electrogram guidance to targe

129 ar tachycardia (VT) in patients with cardiac sarcoidosis can be challenging because of the complex un

130 Nevertheless, the diagnosis of cardiac sarcoidosis can be enhanced by integrating both clinical

131 ificantly higher frequency (48.7%) in ocular sarcoidosis cases (odds ratio, 1.72; 95% confidence inte

132 In a two-stage design, 1,726 German sarcoidosis cases and 5,482 control subjects were genoty

133 Allele frequencies in the ocular sarcoidosis cases were compared with controls using chi-

134 ve for aquaporin-4-immunoglobulin G, and all sarcoidosis cases were pathologically confirmed.

135 PD-1 pathway is an important contributor to sarcoidosis CD4(+) T-cell proliferative capacity and cli

136 Transcriptome analysis of sarcoidosis CD4+ T cells revealed reversal of pathways a

137 edominant producer of IFN-gamma in pulmonary sarcoidosis, challenging the Th1 paradigm of pathogenesi

138 ary sarcoidosis in the study referred to the Sarcoidosis clinic at the Royal Brompton Hospital, UK, b

139 idosis in 13 patients treated at a cutaneous sarcoidosis clinic in a 1-day study on October 24, 2014;

140 rting enzyme level in patients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.00

141 s are significant for patients with presumed sarcoidosis compared to ocular involvement of other auto

142 ercentages of Th17.1 cells in lung lavage in sarcoidosis compared with controls in two separate cohor

143 He was diagnosed pulmonary sarcoidosis complicated with bronchial asthma.

144 The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricul

145 ogy, characteristics, and outcome of cardiac sarcoidosis (CS) in Finland.

146 Cardiac sarcoidosis (CS) may manifest as arrhythmia or even sudd

147 Cardiac sarcoidosis (CS) may show overlap in the clinical presen

148 n emerging modality for diagnosis of cardiac sarcoidosis (CS).

149 Patients with sarcoidosis demonstrate higher T1, extracellular volume,

150 The instrument introduced here captures sarcoidosis disease activity in a reliable, reproducible

151 and nondermatologists in assessing cutaneous sarcoidosis disease activity.

152 s the intensity of their patients' cutaneous sarcoidosis disease activity.

153 nd Severity Index (SASI) to assess cutaneous sarcoidosis disease severity and the Physician's Global

154 No current model of sarcoidosis exists.

155 red with higher frequencies in patients with sarcoidosis, for mitochondrial ribosomal protein L43 esp

156 16 as hypersensitivity pneumonitis, four as sarcoidosis, four as respiratory bronchiolitis, two as o

157 spiral CT, can be useful in differentiating sarcoidosis from Hodgkin's lymphoma.

158 ion is recommended for patients with cardiac sarcoidosis, giant cell myocarditis, and myocarditis ass

159 s revealed increased PD-L1 expression within sarcoidosis granulomas and lung malignancy, but this was

160 severity (healthy control --> uncomplicated sarcoidosis --> complicated sarcoidosis).

161 patients with IgG4-RD, but not patients with sarcoidosis, had increased numbers of circulating plasma

162 Individuals with cardiac sarcoidosis have an increased risk of ventricular arrhyt

163 % to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clini

164 eously achieve full remission (uncomplicated sarcoidosis), however, 20% of sarcoidosis-affected indi

165 omyopathy in 6 patients, for myocarditis and sarcoidosis in 1 patient each.

166 4 rheumatologists evaluated facial cutaneous sarcoidosis in 13 patients treated at a cutaneous sarcoi

167 an association between rs1061170 and ocular sarcoidosis in 2 of 3 genetic models (additive, P = .007

168 MDCT was positive for sarcoidosis in 6 additional patients (80, 89%).

169 and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study.

170 sm of CFH seems to be associated with ocular sarcoidosis in black and white persons.

171 t common pathogenic mechanisms contribute to sarcoidosis in different sites.

172 hat sIL-2R is a useful marker for diagnosing sarcoidosis in patients with uveitis and has slightly be

173 sIL-2R) with ACE as diagnostic biomarkers of sarcoidosis in patients with uveitis.

174 ts for serum sIL-2R and ACE levels to define sarcoidosis in patients with uveitis.

175 ificant differences between tuberculosis and sarcoidosis in the degree of their transcriptional activ

176 patients had evidence of both psoriasis and sarcoidosis in the same cutaneous specimen.

177 highlights the possibility of recurrence of sarcoidosis in the setting of maintenance immunosuppress

178 cohort included 251 patients with pulmonary sarcoidosis in the study referred to the Sarcoidosis cli

179 Peripheral blood monocytes play a role in sarcoidosis inflammation.

180 at activation of p38 plays a pivotal role in sarcoidosis inflammatory response.

181 Gene expression in sarcoidosis involving the orbit or lacrimal gland can be

182 Sarcoidosis is a chronic granulomatous disease for which

183 While sarcoidosis is a chronic granulomatous disease presumabl

184 Sarcoidosis is a chronic multisystem disorder characteri

185 Sarcoidosis is a complex systemic granulomatous disorder

186 Sarcoidosis is a disease involving abnormal collection o

187 Sarcoidosis is a granulomatous disease that primarily af

188 Sarcoidosis is a granulomatous lung disorder of unknown

189 Sarcoidosis is a major cause of ocular or periocular inf

190 Sarcoidosis is a multisystem disease of unknown cause.

191 Sarcoidosis is a multisystem disorder of unknown cause,

192 Sarcoidosis is a multisystem granulomatous disease of un

193 Sarcoidosis is a multisystemic inflammatory disease of u

194 Sarcoidosis is a presumptive autoimmune disorder charact

195 Sarcoidosis is a systemic granulomatous disease of unkno

196 Sarcoidosis is an inflammatory disease that affects mult

197 Sarcoidosis is an inflammatory granulomatous disorder ch

198 RV DE in patients with cardiac sarcoidosis is associated with a risk of adverse events

199 Cardiac sarcoidosis is associated with an increased risk of hear

200 Pulmonary sarcoidosis is classically defined by T-helper (Th) cell

201 Mortality in pulmonary sarcoidosis is highly variable and a reliable prognostic

202 The pathogenesis of sarcoidosis is incompletely understood and diagnosis oft

203 n well documented, and the T(H)17 pathway in sarcoidosis is just now being investigated.

204 lpha agents (anti-TNF) in treating cutaneous sarcoidosis is lacking.

205 which would be useful when the diagnosis of sarcoidosis is not definite.

206 nostic separation of patients with pulmonary sarcoidosis is provided by a simple staging system integ

207 Sarcoidosis is reported to recur after lung transplantat

208 with ocular inflammatory conditions such as sarcoidosis, it does not appear to be unique to AMD but

209 significant reductions in chronic cutaneous sarcoidosis lesion diameter compared with placebo.

210 8; P = .03), and less than 4 extraneurologic sarcoidosis localizations (OR, 3.06; 95% CI, 1.04-8.98;

211 ases, including Crohn's disease, asthma, and sarcoidosis, making signaling proteins downstream of NOD

212 s for PD-1/PD-L1 expression was conducted on sarcoidosis, malignant, and healthy control lung specime

213 Cardiac sarcoidosis may present with heart failure, left ventric

214 Hepatic involvement in sarcoidosis might be a perplexing diagnostic problem.

215 tic granulomatous liver disease secondary to sarcoidosis, mimicking a metastatic disease on ultrasono

216 profile and the cellular pathways altered in sarcoidosis monocytes via RNA-sequencing.

217 ved in phagocytosis and lysosomal pathway in sarcoidosis monocytes, whereas genes involved in proteas

218 hic orbital inflammation (IOI; n = 29; 30%), sarcoidosis (n = 19; 20%), prolapsed LG (n = 15; 15%), l

219 Patients with sarcoidosis (n = 32) were included for detailed analysis

220 ilated cardiomyopathy (n=27), myocarditis or sarcoidosis (n=22), occult myocardial infarction (n=13),

221 recipient with a remote history of pulmonary sarcoidosis on chronic immunosuppression who developed r

222 Later, she was found to have hepatic sarcoidosis on wedge biopsy of the liver.

223 t to (1) determine the prevalence of cardiac sarcoidosis or associated myocardial damage, defined by

224 in the development of pulmonary fibrosis in sarcoidosis or collagen vascular diseases such as system

225 004) recipient body mass index; preoperative sarcoidosis (OR, 2.5; 95% CI, 1.1-5.6; P = 0.03) or pulm

226 The validity of cutaneous sarcoidosis outcome instruments for use across medical s

227 ss the reliability and validity of cutaneous sarcoidosis outcome instruments for use by dermatologist

228 Black patients were more likely to have sarcoidosis (P<0.01).

229 g significantly more likely in patients with sarcoidosis (P<0.05).

230 Sarcoidosis pathogenesis is characterized by peripheral

231 ys and their possible interaction leading to sarcoidosis pathology.

232 ture of monocytes from peripheral blood from sarcoidosis patients and healthy controls via RNA-sequen

233 gnificantly higher NPSR1 levels in sera from sarcoidosis patients compared to healthy controls.

234 pletion from the CD4(+) T cell population of sarcoidosis patients did not rescue IL-2 and IFN-gamma p

235 oRNA-regulated gene signature differentiates sarcoidosis patients from healthy controls in independen

236 52.9% of sarcoidosis patients had monocytes characterised by low

237 A significant proportion of sarcoidosis patients have disease recurrence after LT an

238 However the glucocorticoid-responsive sarcoidosis patients showed a significant increase in tr

239 The HRCT scans of chronic sarcoidosis patients tended to show more atypical sarcoi

240 The sarcoidosis patients were divided into those with uveiti

241 nts at Cleveland Clinic was interrogated for sarcoidosis patients who underwent LT between May 1993 a

242 Sarcoidosis patients with LGE are at significant risk fo

243 In human sarcoidosis patients, mTORC1 activation, macrophage prol

244 lveolar lavage (BAL) cells and leukocytes of sarcoidosis patients.

245 nd elevated blood lysozyme and ACE levels in sarcoidosis patients.

246 idosis patients tended to show more atypical sarcoidosis patterns.

247 creased both IL-1beta and IL-6 production in sarcoidosis PBMCs and moderately in AMs.

248 Increased numbers of sarcoidosis PD-1(+) CD4(+) T cells are present systemica

249 tudinal increase in PDCD1 gene expression in sarcoidosis peripheral blood mononuclear cells.

250 deling on LS and non-LS indicates that these sarcoidosis phenotypes have different genetic susceptibi

251 Sarcoidosis presented with intranodal calcifications mor

252 sing spondylitis, behcet's disease, presumed sarcoidosis, presumed latent tuberculosis, presumed late

253 whole blood and monocytes from patients with sarcoidosis produced more TNF and IL-6 compared with hea

254 e-wide transcriptional profiles in pulmonary sarcoidosis, pulmonary tuberculosis, to community acquir

255 There does not appear to be any impact of sarcoidosis recurrence on 1-, 3-, or 5-year survivals.

256 sensitive and accurate detection of cardiac sarcoidosis remains a challenge.

257 s at baseline) reported data on diagnoses of sarcoidosis, reproductive history, and medication use.

258 nction as a potential therapeutic target for sarcoidosis resolution.

259 functional assays to study CD4(+) T cells in sarcoidosis revealed a marked expansion of Th17.1 cells

260 Longitudinal analysis of subjects with sarcoidosis revealed reduced PD-1(+) CD4(+) T cells with

261 Tuberculosis and sarcoidosis revealed similar blood transcriptional profi

262 fferentially expressed across a continuum of sarcoidosis severity (healthy control --> uncomplicated

263 investigated in another respiratory disease, sarcoidosis, showing significantly higher NPSR1 levels i

264 Heterogeneity of the sarcoidosis signature correlated significantly with dise

265 The Sarcoidosis Assessment Tool (SAT), a sarcoidosis-specific PRO, was administered in a lung and

266 urements to validate it as a useful clinical sarcoidosis-specific PRO.

267 ed that the SAT is a reliable and consistent sarcoidosis-specific PRO.

268 The majority of individuals with sarcoidosis spontaneously achieve full remission (uncomp

269 onsecutive patients with suspected pulmonary sarcoidosis (stage I/II) in whom tissue confirmation of

270 ctivity in 73 BAL samples from subjects with sarcoidosis, subjects with asthma, and healthy subjects.

271 Non-inflammatory effects of sarcoidosis, such as pulmonary hypertension and bronchie

272 Zone 10 was involved more often in sarcoidosis than in Hodgkin's lymphoma.

273 t three cases with a longstanding history of sarcoidosis that have been additionally diagnosed with c

274 yndrome (LS) is a characteristic subgroup of sarcoidosis that is associated with a good prognosis in

275 ranulomatosis, a variant form of "classical" sarcoidosis, that became clinically apparent in the form

276 In sarcoidosis, the proinflammatory cytokines interferon ga

277 to evaluate patients with suspected cardiac sarcoidosis, the relationship between PET findings and c

278 Vaccination responses in patients with sarcoidosis to influenza virus and encapsulated bacteria

279 STAT (Sarcoidosis Treated with Anti-TNF) is a French retrospec

280 fic PRO, was administered in a lung and skin sarcoidosis treatment trial.

281 Furthermore, sarcoidosis Treg cells displayed poor suppressive capaci

282 patients with suspected stage I/II pulmonary sarcoidosis undergoing tissue confirmation, the use of e

283 t was identified with a primary diagnosis of sarcoidosis using International Classification of Diseas

284 diseases such as lymphocytic myocarditis and sarcoidosis) using the gold-standard Dallas criteria.

285 rtality for all patients with a diagnosis of sarcoidosis was 2.0%.

286 of computed tomography (CT), the severity of sarcoidosis was assessed based on chest X-ray abnormalit

287 Recurrence of sarcoidosis was noted among 7 patients (pathological rec

288 Systemic sarcoidosis was present in 39% of patients.

289 vitamin D-binding protein as a biomarker for sarcoidosis, we investigated plasma exosomes from 23 pat

290 Sarcoidosis, Wegener granulomatosis, and pseudorheumatoi

291 Subjects with a diagnosis of sarcoidosis were less likely to require a second-line ag

292 o identify whether findings of extra-cardiac sarcoidosis were present.

293 red as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease.

294 ular ejection fraction >50% and extracardiac sarcoidosis who underwent cardiovascular magnetic resona

295 rols and Caucasian non-smoking patients with sarcoidosis who were not taking disease modifying therap

296 About half of patients with sarcoidosis will need systemic therapy for their disease

297 heumatologists study and treat patients with sarcoidosis with cutaneous manifestations.

298 ings reveal a substantial genetic overlap of sarcoidosis with diverse immune-mediated inflammatory di

299 l was significant for patients with presumed sarcoidosis with respect to ankylosing spondylitis (p =

300 ed for cohort studies of patients with known sarcoidosis with suspected cardiac involvement who under